13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants -

13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants
Information type: Other primary research
Source: Pediatrics
Specialities: Paediatric and neonatal medicine | Vaccination
Summary
Study of 100 preterm and 100 term infants who received PCV13 at ages 2, 3, 4 (infant series), and 12 (toddler dose) months, found although immune response 1-month after infant series was lower in preterm infants, it is likely to provide adequate protection against disease.
UKMi comment
In UK, PCV13 is recommended for infants from two months of age as part of the routine childhood immunisation schedule. It is important that premature infants have their immunisations at the appropriate chronological age, according to the schedule.
Related links: